年龄相关性黄斑变性临床诊疗思路:浅析诊疗指南

Clinical diagnosis and treatment for age-related macular degeneration:a brief analysis of the guidelines

年龄相关性黄斑变性(AMD)是发达国家>65岁人群致盲的常见原因,随着人口老龄化进程加快,AMD患病率将进一步增加。抗血管内皮因子生长(anti-VEGF)药物在眼科的应用使湿性AMD治疗效果和预后都有了长足的进步。基于此背景下,许多国家及地区相继制定AMD临床诊疗指南,尤其美国、欧洲及澳大利亚。通过对美国眼科协会(AAO)2015年AMD临床指南进行解析,并与欧洲视网膜专家协会(EURETINA)2014年AMD诊疗指南比较,旨在为AMD临床诊疗实践提供准确、有效、全面的诊疗策略,为AMD患者提供优质的诊疗计划奠定基础。

Age-related macular degeneration （AMD） is a common cause of blindness among people over 65 in developed countries. With the rapidity of population aging process, the prevalence of AMD will be further increased. The application of anti-vascular endothelial factor growth medicine in ophthalmology has made great progress in the therapeutic effect and prognosis of wet AMD. In this context, many countries and regions have successively formulated guidelines for the AMD clinical diagnosis and treatment, especially the United States, Europe and Australia. Through the analysis of AMD clinical guidelines of American Academy of Ophthalmology （AAO） in 2015, and by comparing it with AMD analysis and treatment guidelines of European Society of Retina Specialists （EURETINA） in 2014, this paper provides an accurate, effective and comprehensive diagnosis strategy and lays a foundation for providing AMD patients with quality diagnosis and treatment plans.